CL2014001726A1 - Composicion farmaceutica que comprende el compuesto a (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-4-acetilaminoisoindolin-1,3-diona, o una sal farmaceuticamente aceptable del mismo, una carga, un disgregante y un lubricante; metodo para tratar, prevenir o manejar una enfermedad o trastorno tal como psoriasis, artritis, dermatitis, acne, enfermedad de crohn, colitis ulcerativa, entre otras. - Google Patents
Composicion farmaceutica que comprende el compuesto a (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-4-acetilaminoisoindolin-1,3-diona, o una sal farmaceuticamente aceptable del mismo, una carga, un disgregante y un lubricante; metodo para tratar, prevenir o manejar una enfermedad o trastorno tal como psoriasis, artritis, dermatitis, acne, enfermedad de crohn, colitis ulcerativa, entre otras.Info
- Publication number
- CL2014001726A1 CL2014001726A1 CL2014001726A CL2014001726A CL2014001726A1 CL 2014001726 A1 CL2014001726 A1 CL 2014001726A1 CL 2014001726 A CL2014001726 A CL 2014001726A CL 2014001726 A CL2014001726 A CL 2014001726A CL 2014001726 A1 CL2014001726 A1 CL 2014001726A1
- Authority
- CL
- Chile
- Prior art keywords
- disease
- acetylaminoisoindolin
- disintegrant
- methanesulfonyl
- acne
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161580626P | 2011-12-27 | 2011-12-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014001726A1 true CL2014001726A1 (es) | 2014-11-14 |
Family
ID=47459206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014001726A CL2014001726A1 (es) | 2011-12-27 | 2014-06-26 | Composicion farmaceutica que comprende el compuesto a (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-4-acetilaminoisoindolin-1,3-diona, o una sal farmaceuticamente aceptable del mismo, una carga, un disgregante y un lubricante; metodo para tratar, prevenir o manejar una enfermedad o trastorno tal como psoriasis, artritis, dermatitis, acne, enfermedad de crohn, colitis ulcerativa, entre otras. |
Country Status (34)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12014500593A1 (en) | 2011-09-14 | 2019-09-02 | Celgene Corp | Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware |
| SG10201605251VA (en) | 2011-12-27 | 2016-08-30 | Celgene Corp | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione |
| EP3143004B1 (en) | 2014-05-11 | 2020-09-02 | Mapi Pharma Limited | Amorphous form of apremilast |
| EP3174999A1 (en) | 2014-07-29 | 2017-06-07 | Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca | Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis |
| PL3316867T3 (pl) * | 2015-06-30 | 2021-10-11 | Genentech, Inc. | Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek |
| CZ20165A3 (cs) * | 2016-01-06 | 2017-07-19 | Zentiva, K.S. | Způsoby přípravy amorfního apremilastu |
| WO2017216738A1 (en) | 2016-06-15 | 2017-12-21 | Torrent Pharmaceuticals Limited | Topical compositions of apremilast |
| KR20220002488A (ko) * | 2019-04-30 | 2022-01-06 | 셀진 코포레이션 | 아프레밀라스트 및 tyk2 억제제를 포함하는 조합 요법 |
| ES2823927B2 (es) * | 2019-11-07 | 2022-01-18 | Beijing Enbiwo Biological Tech Co Ltd | Composición en tamaño micrométrico y su uso como agente coadyuvante de alcaloides vegetales |
| KR20220047105A (ko) | 2020-10-08 | 2022-04-15 | 주식회사 엔비피헬스케어 | 아프레밀라스트를 함유하는 약학 조성물 |
| CN112245403B (zh) * | 2020-10-23 | 2022-04-22 | 杭州朱养心药业有限公司 | 磷酸二酯酶-4抑制剂及其口服固体组合物 |
| EP4183389A1 (en) | 2021-11-18 | 2023-05-24 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising apremilast |
| WO2023118043A1 (en) | 2021-12-22 | 2023-06-29 | Biohorm, S.L. | Pharmaceutical compositions of apremilast |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5358941A (en) * | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| WO1995003807A1 (en) | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
| IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| PL195916B1 (pl) | 1996-07-24 | 2007-11-30 | Celgene Corp | Izomery optyczne podstawionej 1-okso-izoindoliny i 1,3-diokso-izoindoliny, kompozycje farmaceutyczne je zawierające oraz ich zastosowanie |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US6448323B1 (en) | 1999-07-09 | 2002-09-10 | Bpsi Holdings, Inc. | Film coatings and film coating compositions based on polyvinyl alcohol |
| EA200200502A1 (ru) * | 1999-10-29 | 2002-10-31 | Смитклайн Бичам Корпорейшн | Способ введения ингибитора фосфодиэстеразы 4 |
| US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| AU2002343220A1 (en) | 2001-11-09 | 2003-05-19 | Matsushita Electric Industrial Co., Ltd. | Moving picture coding method and apparatus |
| MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| KR20060109979A (ko) | 2003-12-02 | 2006-10-23 | 셀진 코포레이션 | 혈색소병증 및 빈혈의 치료 및 관리를 위한 방법및 조성물 |
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| KR101224262B1 (ko) | 2004-03-22 | 2013-01-21 | 셀진 코포레이션 | 면역조절 화합물을 포함하는 피부 질환 또는 장애의 치료및 관리용 조성물 및 이의 사용 방법 |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| CN101163489A (zh) | 2004-04-23 | 2008-04-16 | 细胞基因公司 | 用于治疗和控制肺高血压的包含免疫调节化合物的组合物及其使用方法 |
| KR20070086000A (ko) | 2004-11-12 | 2007-08-27 | 셀진 코포레이션 | 기생충성 질병의 치료 및 관리를 위한 면역조절성 화합물을사용하는 방법 및 조성물 |
| EP1827431A1 (en) | 2004-11-23 | 2007-09-05 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
| CA2588990A1 (en) | 2004-12-01 | 2006-06-08 | Celgene Corporation | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
| AU2006214021A1 (en) * | 2005-02-15 | 2006-08-24 | Wyeth | Orally bioavailable CCI-779 tablet formulations |
| EP1858514B1 (en) * | 2005-03-17 | 2014-11-26 | Synthon B.V. | Pharmaceutical tablets of crystalline type ii aripiprazole |
| WO2006111980A2 (en) | 2005-04-20 | 2006-10-26 | Ideal Cures Pvt. Ltd. | Pva based film coating and film coating compositions |
| EP1928492B1 (en) | 2005-09-01 | 2011-02-23 | Celgene Corporation | Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy |
| US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
| US8927546B2 (en) * | 2006-02-28 | 2015-01-06 | Dart Neuroscience (Cayman) Ltd. | Therapeutic piperazines |
| CN102046167A (zh) * | 2008-03-27 | 2011-05-04 | 细胞基因公司 | 包含(+)-2-[1-(3-乙氧基-4-甲氧基苯基)-2-甲基磺酰基乙基]-4-乙酰基氨基异吲哚啉-1,3-二酮的固体形式、其组合物及其用途 |
| DE102008047910A1 (de) * | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
| EP2196465A1 (en) * | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| AU2010213936B2 (en) | 2009-02-10 | 2014-07-31 | Celgene Corporation | Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management of tuberculosis |
| ES2693686T3 (es) * | 2009-11-13 | 2018-12-13 | Astrazeneca Ab | Formulaciones de comprimidos de liberación inmediata |
| JP6143675B2 (ja) * | 2010-12-16 | 2017-06-07 | セルジーン コーポレイション | 難溶性薬物の制御放出経口剤形及びその使用 |
| SG10201605251VA (en) | 2011-12-27 | 2016-08-30 | Celgene Corp | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione |
-
2012
- 2012-12-26 SG SG10201605251VA patent/SG10201605251VA/en unknown
- 2012-12-26 WO PCT/US2012/071623 patent/WO2013101810A1/en not_active Ceased
- 2012-12-26 EP EP25181548.6A patent/EP4623993A3/en active Pending
- 2012-12-26 ES ES12808662T patent/ES2799448T3/es active Active
- 2012-12-26 HR HRP20200825TT patent/HRP20200825T1/hr unknown
- 2012-12-26 EA EA201491292A patent/EA027801B1/ru not_active IP Right Cessation
- 2012-12-26 KR KR1020197030218A patent/KR102232154B1/ko active Active
- 2012-12-26 PE PE2014001038A patent/PE20142318A1/es not_active Application Discontinuation
- 2012-12-26 LT LTEP12808662.6T patent/LT2797581T/lt unknown
- 2012-12-26 JP JP2014550424A patent/JP6161629B2/ja active Active
- 2012-12-26 AU AU2012362562A patent/AU2012362562B2/en active Active
- 2012-12-26 KR KR1020217008170A patent/KR20210033073A/ko not_active Ceased
- 2012-12-26 HU HUE12808662A patent/HUE050327T2/hu unknown
- 2012-12-26 PT PT128086626T patent/PT2797581T/pt unknown
- 2012-12-26 HR HRP20251291TT patent/HRP20251291T1/hr unknown
- 2012-12-26 LT LTEP20172615.5T patent/LT3756650T/lt unknown
- 2012-12-26 EP EP12808662.6A patent/EP2797581B1/en not_active Revoked
- 2012-12-26 RS RS20251057A patent/RS67339B1/sr unknown
- 2012-12-26 PL PL12808662T patent/PL2797581T3/pl unknown
- 2012-12-26 SM SM20250402T patent/SMT202500402T1/it unknown
- 2012-12-26 SG SG11201403564YA patent/SG11201403564YA/en unknown
- 2012-12-26 CN CN201280070694.5A patent/CN104136003A/zh active Pending
- 2012-12-26 RS RS20200715A patent/RS60415B1/sr unknown
- 2012-12-26 BR BR112014015923-8A patent/BR112014015923B1/pt active IP Right Grant
- 2012-12-26 SM SM20200339T patent/SMT202000339T1/it unknown
- 2012-12-26 DK DK20172615.5T patent/DK3756650T3/da active
- 2012-12-26 KR KR1020147020953A patent/KR102035362B1/ko active Active
- 2012-12-26 EP EP20172615.5A patent/EP3756650B1/en active Active
- 2012-12-26 UA UAA201408510A patent/UA113750C2/uk unknown
- 2012-12-26 PT PT201726155T patent/PT3756650T/pt unknown
- 2012-12-26 SI SI201231796T patent/SI2797581T1/sl unknown
- 2012-12-26 CA CA2861594A patent/CA2861594A1/en active Pending
- 2012-12-26 FI FIEP20172615.5T patent/FI3756650T3/fi active
- 2012-12-26 US US13/727,366 patent/US20130164376A1/en not_active Abandoned
- 2012-12-26 MX MX2014007878A patent/MX373934B/es active IP Right Grant
- 2012-12-26 DK DK12808662.6T patent/DK2797581T3/da active
-
2014
- 2014-06-22 IL IL233296A patent/IL233296B/en active IP Right Grant
- 2014-06-24 ZA ZA2014/04629A patent/ZA201404629B/en unknown
- 2014-06-26 MX MX2020005145A patent/MX2020005145A/es unknown
- 2014-06-26 CL CL2014001726A patent/CL2014001726A1/es unknown
- 2014-06-26 NI NI201400068A patent/NI201400068A/es unknown
- 2014-06-27 PH PH12014501495A patent/PH12014501495A1/en unknown
- 2014-06-27 CR CR20140314A patent/CR20140314A/es unknown
- 2014-07-03 EC ECIEPI20147965A patent/ECSP14007965A/es unknown
- 2014-07-09 CO CO14147911A patent/CO7000777A2/es unknown
-
2020
- 2020-05-14 US US16/874,424 patent/US20210093573A1/en active Pending
- 2020-06-25 CY CY20201100590T patent/CY1123174T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014001726A1 (es) | Composicion farmaceutica que comprende el compuesto a (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-4-acetilaminoisoindolin-1,3-diona, o una sal farmaceuticamente aceptable del mismo, una carga, un disgregante y un lubricante; metodo para tratar, prevenir o manejar una enfermedad o trastorno tal como psoriasis, artritis, dermatitis, acne, enfermedad de crohn, colitis ulcerativa, entre otras. | |
| CL2013002612A1 (es) | Compuestos derivados de c4-monometil triterpenoides; composicion farmaceutica que los comprende; y metodo para tratar o prevenir una enfermedad o un trastorno. | |
| ECSP13013060A (es) | Composiciones de nucleasa terapéuticas y métodos | |
| PH12014501656B1 (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
| CL2013001982A1 (es) | Metodo para reducir los niveles de glucosa y tratar trastornos del metabolismo de la misma; composicion farmaceutica que comprende metformina y otro agente antidiabetico o antiobesidad. | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| ECSP14017584A (es) | Compuestos inhibidores de raf | |
| PE20150887A1 (es) | Compuestos de benceno sustituidos | |
| BR112016009889A2 (pt) | ?compostos agonistas duplos gip-glp-1 e métodos? | |
| CL2013001602A1 (es) | Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple. | |
| UY35962A (es) | Formulaciones de liberación modificada de pridopidina | |
| DOP2015000140A (es) | Compuesto heterocíclico | |
| CL2018000739A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma. | |
| CL2015000946A1 (es) | Compuestos derivados de quinolinilo unidos a fenilo; composicion farmaceutica y su proceso de elaboracion; un metodo para tratar o mejorar un sindrome trastorno, o enfermedad inflamatoria mediada por ror-gamma-t, tal como artritis reumatoide, psoriasis, enfermedad de crohn, entre otras. | |
| GT201200164A (es) | "nuevos compuestos de espiropiperidina" | |
| CR20140036A (es) | Compuesto inhibidor de la señalización de la trayectoria notch | |
| PE20140255A1 (es) | Tableta dispersable en forma oral | |
| MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| CL2015001610A1 (es) | Compuestos derivados de pirimido-[4,5-b]-quinolina-4,5(3h,10h)-dionas para utilizarse como un medicamento para el tratamiento de una enfermedad causada por una mutacion sin sentido; composicion y combinacion farmaceutica que los comprende. | |
| MX2016008429A (es) | Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria. | |
| CL2014003429A1 (es) | Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia. | |
| MX350666B (es) | Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia. | |
| CO7071139A2 (es) | Tratamiento contra el cáncer cerebral | |
| AR085616A1 (es) | Composicion farmaceutica inhalable que comprende glicopirrolato, uso | |
| CL2015000434A1 (es) | Metodo para el tratamiento, prevencion o disminucion de la severidad de una condicion o trastorno no neoplasico de la piel que comprende administrar un compuesto derivado de retinoides; composicion dermica que comprende los derivados de retinoide. |